The first stage of the trial, which involved
an analysis of circulating tumor cells from a single blood draw of several dozen patients, has demonstrated strong potential.
Not exact matches
Adds Liu: «With metastatic cancers accounting for around 90 %
of deaths from solid
tumors, the hope is that one day a device that can enable the
analysis of single
tumor cells circulating in the blood could make a big difference in early diagnosis, detection and monitoring
of numerous types
of cancer, without invasive biopsies.»
The role
of rebiopsy and repeat
analysis in the setting
of post-treatment relapse, along with testing
of blood samples for mutations in
circulating tumor cells,
cell free
tumor DNA, or exosomes will be considered.
He noted that there are some ongoing studies that may further inform this difference in the future, including
tumor DNA
analysis with whole exome sequencing and
tumor RNA
analysis with RNAseq, evaluation
of circulating cell - free
tumor DNA, and hypermethylation.
Analysis of circulating cell - free DNA (cfDNA) reveals reversion mutation heterogeneity not discernable from a single solid -
tumor biopsy and potentially allows monitoring for the emergence
of PARPi resistance.
Blood - Based
Analyses of Cancer:
Circulating Tumor Cells and
Circulating Tumor DNA.
We conducted a meta -
analysis in nonmetastatic breast cancer patients treated by neoadjuvant chemotherapy (NCT) to assess the clinical validity
of circulating tumor cell (CTC) detection as a prognostic marker.